Korro Bio is trading at $9.62, down 5.31%, with no clear company-specific catalyst identified for its October 12 decline. - The first-cohort dosing announcement for KRRO-121 was reported October 5, not October 12. - Market context was mixed, while coverage described biotechnology shares gaining; neither explains the stock’s drop. - October 12 trading volume or activity was not established in the available sources.